Wave Life Sciences Enters Material Definitive Agreement
Ticker: WVE · Form: 8-K · Filed: Sep 26, 2024 · CIK: 1631574
| Field | Detail |
|---|---|
| Company | Wave Life Sciences Ltd. (WVE) |
| Form Type | 8-K |
| Filed Date | Sep 26, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0, $8.00, $7.9999, $0.0001, $200 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, regulation-fd
TL;DR
Wave Life Sciences signed a big deal, details to come.
AI Summary
Wave Life Sciences Ltd. announced on September 25, 2024, that it entered into a material definitive agreement. The company also disclosed information under Regulation FD and reported other events, including financial statements and exhibits. Specific details of the agreement and financial figures were not provided in this initial filing.
Why It Matters
This filing indicates a significant new agreement for Wave Life Sciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, but the lack of specific details about the agreement's terms and financial implications introduces uncertainty.
Key Players & Entities
- Wave Life Sciences Ltd. (company) — Registrant
- September 25, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Wave Life Sciences?
The filing states that Wave Life Sciences Ltd. entered into a material definitive agreement on September 25, 2024, but does not provide specific details about the agreement's terms or counterparty.
What other information is disclosed in this 8-K filing?
In addition to the material definitive agreement, the filing includes disclosures under Regulation FD, reports on other events, and provides financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on September 25, 2024.
What is the exact name of the registrant?
The exact name of the registrant is Wave Life Sciences Ltd.
What is the Commission File Number for Wave Life Sciences Ltd.?
The Commission File Number for Wave Life Sciences Ltd. is 001-37627.
Filing Stats: 1,336 words · 5 min read · ~4 pages · Grade level 10.8 · Accepted 2024-09-26 17:18:58
Key Financial Figures
- $0 — of each exchange on which registered $0 Par Value Ordinary Shares WVE The N
- $8.00 — Shares"), at a public offering price of $8.00 per Share (as defined below), and, in l
- $7.9999 — ry shares at a public offering price of $7.9999 per Pre-Funded Warrant, which represent
- $0.0001 — offering price for the Shares less the $0.0001 per share exercise price for each Pre-F
- $200 million — fering are expected to be approximately $200 million before deducting underwriting discounts
Filing Documents
- d817468d8k.htm (8-K) — 36KB
- d817468dex11.htm (EX-1.1) — 328KB
- d817468dex41.htm (EX-4.1) — 65KB
- d817468dex51.htm (EX-5.1) — 58KB
- d817468dex52.htm (EX-5.2) — 15KB
- d817468dex991.htm (EX-99.1) — 9KB
- g817468dsp49a.jpg (GRAPHIC) — 3KB
- g817468dsp49b.jpg (GRAPHIC) — 2KB
- g817468dsp54.jpg (GRAPHIC) — 3KB
- g817468dsp55.jpg (GRAPHIC) — 4KB
- g817468dsp56.jpg (GRAPHIC) — 2KB
- g817468g0926092549079.jpg (GRAPHIC) — 3KB
- 0001193125-24-227053.txt ( ) — 787KB
- wve-20240925.xsd (EX-101.SCH) — 3KB
- wve-20240925_lab.xml (EX-101.LAB) — 18KB
- wve-20240925_pre.xml (EX-101.PRE) — 11KB
- d817468d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated September 25, 2024, by and between the Company and J.P. Morgan Securities LLC and Leerink Partners LLC. 4.1 Form of Pre-Funded Warrant. 5.1 Opinion of WongPartnership LLP. 5.2 Opinion of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. 99.1 Press Release of Wave Life Sciences Ltd., dated September 25, 2024, announcing the pricing of the underwritten offering. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WAVE LIFE SCIENCES LTD. By: /s/ Paul B. Bolno, M.D. Paul B. Bolno, M.D. President and Chief Executive Officer Date: September 26, 2024